Innovative drugs soothe Fosun Pharma from pain of fading Covid vaccine
With China's pandemic controls ending and the WHO adjusting its vaccination recommendations, demand for the company’s comirnaty vaccine is plunging Key takeaways: Fosun Pharma's net profit fell more than 20%…
Junshi Biosciences Hits Revenue Roadblock Amid Covid Drug Delay
Junshi Biosciences is facing business headwinds. Its key cancer drug has not sold as well as competing products and the company has yet to file a marketing application for its…
Genuine Biotech Seeks IPO Booster from New Oral Covid Drug
Company hopes China’s approval of its small molecule oral Covid-19 drug will draw investors to its newly filed listing plan Key Takeaways: Genuine Biotech has filed to list in Hong…
RELATED ARTICLES
-
Debt pressures cast cloud over Fosun Pharma results
2196.HK 600196.SHG -
Fosun Tourism at crossroads as parent shops its two major assets
1992.HK 0656.HK
- Health Guard plans dual listing to fund HPV vaccine fight
-
Fosun Tourism embarks on new journey with departure of big-name director
1992.HK
-
Profit setback for Simcere Pharma in novel drugs quest
2096.HK
